Sydney, Australia - Asia-Pacific specialist CRO Novotech has welcomed the announcement that it is a finalist in the prestigious NSW International Health Awards 2019.
The NSW Awards are an annual program which aims to recognise excellence in the provision of global services.
The panelists considered the following key facts in selecting Novotech as a finalist:
- Novotech has supported its expansion into Asia with the signing of over 20 formal partnerships with key hospitals in South Korea, Greater China, Thailand, Singapore, India and Malaysia to facilitate the project management of clinical trials for its biotech clients.
- Novotech's activity in Asian countries increased by over 40% over the last 12 months.
- Novotech staff numbers have grown by about 45% in Asia over the last year fueled by the demand for a regional CRO with international accreditation and expertise.
- Novotech's international model strongly relies on experienced leadership with a deep understanding of the local environment. Customers' value Novotech's regional expertise as clinical trials are becoming larger and more complex.
- Novotech's investment in clinical consulting will provide additional client support to develop and implement client R&D plans.
- Novotech is very much focused on the biotech sector and Asia-Pacific. The clinical activity of biotech companies has increased by about 10% each year on average in the last 2 years, while the growth in biotech activity in Asia-Pacific is up by 26% on average over the last 2 years.
Novotech CEO Dr John Moller said:
"The Novotech team across our 11 offices in the Asia-Pacific is very excited that the company was selected as a finalist, he said.
"While there are always new players trying to tap into the region, biotechs recognise that Novotech has a proven track-record and experience spanning more than 2 decades in the Asia-Pacific, and award nominations like this again confirm our leadership in the sector."
Novotech, known as the Asia-Pacific CRO, has offices and teams through the region as well as partnerships and long-term relationships with major hospitals that directly benefit clients.
Novotech's in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets.
Novotech was established in 1996, headquartered in Australia with offices in 11 countries across the region, and 3 customer-facing offices in the United States.
The winner will be announced at an industry event on October 16, 2019.
About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.
For RFP
